Skip to main content
Erschienen in: Medical Oncology 1/2011

01.12.2011 | Original Paper

Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients

verfasst von: Xiang Da Dong, Brian I. Carr

Erschienen in: Medical Oncology | Sonderheft 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Neuroendocrine tumors (NETs) of the gastrointestinal tract have a propensity for hepatic metastases. Surgical resection for hepatic metastases remains the gold standard for long-term survival, but many patients present with multifocal tumors, precluding surgery with increasing use of chemoembolization. However, there are few studies examining long-term survival factors. We reviewed our 15-year experience with chemoembolization in 123 patients with unresectable NET liver metastases, whose prognosis was evaluated upon baseline clinical factors. There were 64 males (53%) and 59 females (47%). Average age at presentation was 56 years (range: 14.3–85.5 years). Abdominal pain (44%) was the most common presenting symptom, followed by diarrhea (30%) and weight lost (22%). Patients underwent an average 7.3 cycles of chemoembolization (range 1–32 cycles). Responses: 62% of patients had PR; 24% had stable disease and 14% had tumor progression. Overall 3-, 5- and 10-year survivals were 59, 36 and 20% of patients with a mean follow-up of 3.2 years (range 2 weeks–18.3 years) and mean survival of 3.3 years. Univariate analysis showed that age greater than 60 years had worse outcome (P < 0.01), as did baseline serum albumin of ≤3.5 g/dL and prothrombin time >13 s. Location of the primary tumor (P = 0.68), gender (P = 0.4) and serum NET peptide levels did not influence survival. However, multivariate analysis showed that a low baseline serum albumin level was an independent factor for prognosis (P = 0.003). Chemoembolization for unresectable NETs metastatic to liver is useful for tumor size reduction, symptom palliation and can be associated with prolonged survival.
Literatur
1.
Zurück zum Zitat O’Toole D, Maire F, Ruszniewski P. Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Relat Cancer. 2003;10:463–8.PubMedCrossRef O’Toole D, Maire F, Ruszniewski P. Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Relat Cancer. 2003;10:463–8.PubMedCrossRef
2.
Zurück zum Zitat Creutzfeldt W. Carcinoid tumors: development of our knowledge. World J Surg. 1996;20:126–31.PubMedCrossRef Creutzfeldt W. Carcinoid tumors: development of our knowledge. World J Surg. 1996;20:126–31.PubMedCrossRef
3.
Zurück zum Zitat Lips CJ, Lentjes EGWM, Hoppener JWM. The spectrum of carcinoid tumours and carcinoid syndromes. Ann Clin Biochem. 2003;40:612–27.PubMedCrossRef Lips CJ, Lentjes EGWM, Hoppener JWM. The spectrum of carcinoid tumours and carcinoid syndromes. Ann Clin Biochem. 2003;40:612–27.PubMedCrossRef
4.
Zurück zum Zitat Moertel CG. Karnofsky memorial lecture: an odyssey in the land of small tumors. J Clin Oncol. 1987;5(10):1503–22. Moertel CG. Karnofsky memorial lecture: an odyssey in the land of small tumors. J Clin Oncol. 1987;5(10):1503–22.
5.
Zurück zum Zitat Berge T, Linell F. Carcinoid tumors, frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand A. 1976;84:322–30.PubMed Berge T, Linell F. Carcinoid tumors, frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand A. 1976;84:322–30.PubMed
6.
Zurück zum Zitat Bax N, Woods H, Batchelor A, Jennings M. Clinical manifestations of carcinoid disease. World J Surg. 1996;20:142–6.PubMedCrossRef Bax N, Woods H, Batchelor A, Jennings M. Clinical manifestations of carcinoid disease. World J Surg. 1996;20:142–6.PubMedCrossRef
7.
Zurück zum Zitat Proye C. Natural history of liver metastasis of gastroenteropancreatic neuroendocrine tumors: place for chemoembolization. World J Surg. 2001;25:685–8.PubMedCrossRef Proye C. Natural history of liver metastasis of gastroenteropancreatic neuroendocrine tumors: place for chemoembolization. World J Surg. 2001;25:685–8.PubMedCrossRef
8.
Zurück zum Zitat Shebani KO, Souba WW, Finkelstein DM, Stark PC, Elgadi KM, Tanabe KK, et al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg. 1999;229(6):815–23.PubMedCrossRef Shebani KO, Souba WW, Finkelstein DM, Stark PC, Elgadi KM, Tanabe KK, et al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg. 1999;229(6):815–23.PubMedCrossRef
9.
Zurück zum Zitat Pape U-F, Bohmig M, Berndt U, Tiling N, Wiedenmann B, Plockinger U. Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center. Ann N Y Acad Sci. 2004;1014:222–33.PubMedCrossRef Pape U-F, Bohmig M, Berndt U, Tiling N, Wiedenmann B, Plockinger U. Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center. Ann N Y Acad Sci. 2004;1014:222–33.PubMedCrossRef
10.
Zurück zum Zitat Woodside KJ, Townsend CM, Evers BM. Current management of gastrointestinal carcinoid tumors. J Gastrointest Surg. 2004;8(6):742–56.PubMedCrossRef Woodside KJ, Townsend CM, Evers BM. Current management of gastrointestinal carcinoid tumors. J Gastrointest Surg. 2004;8(6):742–56.PubMedCrossRef
11.
Zurück zum Zitat Yao KA, Talamonti MS, Nemcek A, Angelos P, Chrisman H, Skarda J, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001;130(4):677–85.PubMedCrossRef Yao KA, Talamonti MS, Nemcek A, Angelos P, Chrisman H, Skarda J, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001;130(4):677–85.PubMedCrossRef
12.
Zurück zum Zitat Siperstein AE, Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg. 2001;25(6):693–6.PubMedCrossRef Siperstein AE, Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg. 2001;25(6):693–6.PubMedCrossRef
13.
Zurück zum Zitat Florman S, Toure B, Kim L, Gondolesi G, Roayaie S, Krieger N, et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg. 2004;8(2):208–12.PubMedCrossRef Florman S, Toure B, Kim L, Gondolesi G, Roayaie S, Krieger N, et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg. 2004;8(2):208–12.PubMedCrossRef
14.
Zurück zum Zitat Azimuddin K, Chamberlain RS. The surgical management of pancreatic neuroendocrine tumors. Surg Clin North Am. 2001;81(3):511–25.PubMedCrossRef Azimuddin K, Chamberlain RS. The surgical management of pancreatic neuroendocrine tumors. Surg Clin North Am. 2001;81(3):511–25.PubMedCrossRef
15.
Zurück zum Zitat Sutcliffe R, Maguire D, Ramage J, Rela M, Heaton N. Management of neuroendocrine liver metastases. Am J Surg. 2004;187:39–46.PubMedCrossRef Sutcliffe R, Maguire D, Ramage J, Rela M, Heaton N. Management of neuroendocrine liver metastases. Am J Surg. 2004;187:39–46.PubMedCrossRef
16.
Zurück zum Zitat Chamberlain R, Canes D, Brown K, Saltz L, Jarnagin W, Fong Y, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190(4):432–45.PubMedCrossRef Chamberlain R, Canes D, Brown K, Saltz L, Jarnagin W, Fong Y, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190(4):432–45.PubMedCrossRef
17.
Zurück zum Zitat Nave H, Mossinger E, Feist H, Lang H, Raab H-R. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery. 2001;129:170–5.PubMedCrossRef Nave H, Mossinger E, Feist H, Lang H, Raab H-R. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery. 2001;129:170–5.PubMedCrossRef
18.
Zurück zum Zitat Roche A, Girish BV, de Baere T, Baudin E, Boige V, Elias D, et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol. 2003;13:136–40.PubMed Roche A, Girish BV, de Baere T, Baudin E, Boige V, Elias D, et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol. 2003;13:136–40.PubMed
19.
Zurück zum Zitat Allison D, Modlin I, Jenkins W. Treatment of carcinoid liver metastases by hepatic-artery embolisation. Lancet. 1977;2(8052–8053):1323–5.PubMedCrossRef Allison D, Modlin I, Jenkins W. Treatment of carcinoid liver metastases by hepatic-artery embolisation. Lancet. 1977;2(8052–8053):1323–5.PubMedCrossRef
20.
Zurück zum Zitat Drougas JG, Anthony LB, Blair TK, Lopez RR, Wright JK, Chapman WC, et al. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg. 1998;175:408–12.PubMedCrossRef Drougas JG, Anthony LB, Blair TK, Lopez RR, Wright JK, Chapman WC, et al. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg. 1998;175:408–12.PubMedCrossRef
21.
Zurück zum Zitat Carr BI, Kondragunta V, Buch S, Branch R. Therapeutic equivalence in survival for hepatic arterial chemoembolization and 90Yttrium microspheres (Y90) treatments in unresectable HCC. Cancer. 2010;116:1305–14.PubMedCrossRef Carr BI, Kondragunta V, Buch S, Branch R. Therapeutic equivalence in survival for hepatic arterial chemoembolization and 90Yttrium microspheres (Y90) treatments in unresectable HCC. Cancer. 2010;116:1305–14.PubMedCrossRef
22.
Zurück zum Zitat Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 2003;9(4):261–7.PubMedCrossRef Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 2003;9(4):261–7.PubMedCrossRef
23.
Zurück zum Zitat Vogl TJ, Gruber T, Naguib NNN, Hammersting R, Nour-Eldin NA. Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols. Am J Roentgen. 2009;193:941–7.CrossRef Vogl TJ, Gruber T, Naguib NNN, Hammersting R, Nour-Eldin NA. Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols. Am J Roentgen. 2009;193:941–7.CrossRef
24.
Zurück zum Zitat Carr BI, Buch SC, Kondragunta V, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable HCC: a case cohort study. J Gastroenterol Hepatol. 2008;23:1259–66.PubMedCrossRef Carr BI, Buch SC, Kondragunta V, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable HCC: a case cohort study. J Gastroenterol Hepatol. 2008;23:1259–66.PubMedCrossRef
Metadaten
Titel
Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients
verfasst von
Xiang Da Dong
Brian I. Carr
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe Sonderheft 1/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9750-6

Weitere Artikel der Sonderheft 1/2011

Medical Oncology 1/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.